



# Ultrathin Supraflex Stent Shows Superior Efficacy And Identical Safety Vs Xience Family

**ALL-COMERS PATIENT POPULATION**  
7 COUNTRIES IN EUROPE • 23 CENTRES • 1435 PATIENTS

## ITT - INTENTION TO TREAT

### TLF or DOCE

**4.9%**

SUPRAFLEX

**5.3%**

XIENCE

### ST

**0.8%**

SUPRAFLEX

**0.9%**

XIENCE

### TLR

**2.7%**

SUPRAFLEX

**4.0%**

XIENCE

## PER PROTOCOL BASIS

### CI-TLR

**1.2%**

SUPRAFLEX

**3.1%**

XIENCE

### DOCE

**3.5%**

SUPRAFLEX

**4.4%**

XIENCE

## CONCLUSION

The ultrathin Supraflex biodegradable polymer SES was non-inferior to the Xience durable polymer EES for DOCE at 12 months in an all-comer population with a lower rate of CI-TLR in the per protocol analysis.

In per protocol analysis (only study stent used, no crossover to any other stent) Supraflex shows significant 61% reduction in Clinically Indicated TLR as compared to Xience stent.

The Definite and Probable stent thrombosis shows no difference in outcome.